Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Rapid-response vaccines—does DNA offer a solution?

Nature Biotechnology volume 23, pages 1059–1062 (2005)Cite this article

In responding to future influenza pandemics and other infectious agents, plasmid DNA overcomes many of the limitations of conventional vaccine production approaches.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic of the time scale for the development of a vaccine.
Figure 2: Plot showing increasing usage of naked/plasmid DNA in gene therapy trials throughout the world29.

References

  1. Institute of Medicine. Forum on Microbial Threats, Board on Global Health. The Threat of Pandemic Influenza: Are We Ready? (US National Academy of Sciences, Washington, DC, 2004).

  2. http://www.who.int/csr/disease/avian_influenza/country/en/

  3. World Health Organization. Epidemic Alert and Response: Vaccines for Pandemic Influenza. Summary Report (WHO, Geneva, 2004).

  4. Check, E. Nature 435, 404–406 (2005).

    Article  CAS  Google Scholar 

  5. Plotkin, S.A. Health Affairs 24, 631–634 (2005)

    Article  Google Scholar 

  6. Sellers, L.J. Pharmaceutical Executive 24, 60–70 (May 2004).

    Google Scholar 

  7. Global Alliance for Vaccines and Immunization. Immunization Financing Options. (GAVI, Geneva, Switzerland, 2004) http://www.who.int/immunization_financing/options/briefcase/en/.

  8. Wahlberg, D. & Seabrook, C. Flu vaccine production system shaky. New York Times Syndicate (October 10, 2004).

    Google Scholar 

  9. Subbarao, K. et al. Virology 305, 192–200 (2003).

    Article  CAS  Google Scholar 

  10. Lipatov, A.S., Webby, R.J., Govorkova, E.A., Krauss, S. & Webster, R.G. J. Infect. Dis. 191, 1216–1220 (2005).

    Article  CAS  Google Scholar 

  11. Webby, R.J. et al. Lancet 363, 1099–1103 (2004).

    Article  CAS  Google Scholar 

  12. Hehme, N., Engelmann, H., Kuenzel, W., Neumeier, E. & Saenger, R. Virus Res. 103, 163–171 (2004).

    Article  CAS  Google Scholar 

  13. Wolff, J.A. et al. Science 247, 1465–1468 (1990).

    Article  CAS  Google Scholar 

  14. Michel, M. et al. Proc. Natl. Acad. Sci. USA 92, 5307–5311 (1995).

    Article  CAS  Google Scholar 

  15. Davis, H.L. Curr. Opin. Biotechnol. 8, 635–640 (1997).

    Article  CAS  Google Scholar 

  16. Diogo, M.M. et al. J. Gene Med. 3, 577–584 (2001).

    Article  CAS  Google Scholar 

  17. Johansen, P. et al. Immunol. Lett. 90, 81–85 (2003).

    Article  CAS  Google Scholar 

  18. Bouchie, A. Nat. Biotechnol. 21, 11 (2003).

    Google Scholar 

  19. Ulmer, J.B. et al. Science 259, 1745–1749 (1993).

    Article  CAS  Google Scholar 

  20. Weiss, R. West Nile's widening toll. Washington Post (p A01, 28 December 2002). http://www.washingtonpost.com/wp-dyn/articles/A45800-2002Dec27.html

  21. Scherman, D. Bulletin de l Academie Nationale de Medecine 185, 1683–1697 (2001).

    Google Scholar 

  22. McDonnell, W.M. & Askari, F.K. N. Engl. J. Med. 335, 42–45 (1996).

    Article  Google Scholar 

  23. UK Vaccine Industry Group. Production: How are Vaccines Made? (Association of the British Pharmaceutical Industry, London, UK, 2004) http://www.uvig.org/

  24. http://www.aldevron.com/pdf/West_Nile_Virus_Vaccine.pdf (2003).

  25. Boehringer Ingelheim. Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale. UK Patent WO03051483 (2003).

  26. Chase, H.A. J. Mol. Recogn. 11, 217–221 (1998).

    Article  CAS  Google Scholar 

  27. Woodgate, J., Palfrey, D., Nagel, D.A., Hine, A.V. & Slater, N.K.H. Biotechnol. Bioeng. 79, 411–418 (2002).

    Article  Google Scholar 

  28. Agrawal, S. & Kandimalla, E.R. Nat. Biotechnol. 22, 1533–1537 (2004).

    Article  CAS  Google Scholar 

  29. Journal of Gene Medicine. Gene Therapy Clinical Trials Worldwide (New York, John Wiley and Sons, 2004). http://www.wiley.co.uk/genetherapy/clinical/

  30. World Health Organization. Influenza Pandemic Preparedness and Response (WHO, Geneva, 2005). http://www.who.int/gb/ebwha/pdf_files/EB115/B115_44-en.pdf

Download references

Author information

Authors and Affiliations

  1. research fellow of the Department of Chemical Engineering, Victorian Endowment for Science, Knowledge, and Innovation (VESKI), Monash University, Clayton, 3800, Melbourne, Australia

    Gareth M Forde

Authors
  1. Gareth M Forde
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forde, G. Rapid-response vaccines—does DNA offer a solution?. Nat Biotechnol 23, 1059–1062 (2005). https://doi.org/10.1038/nbt0905-1059

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0905-1059

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing